{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:43:57Z","timestamp":1787805837875,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1097\/gco.0b013e32831da80e","type":"journal-article","created":{"date-parts":[[2009,1,6]],"date-time":"2009-01-06T03:52:04Z","timestamp":1231213924000},"page":"60-67","source":"Crossref","is-referenced-by-count":26,"title":["Aromatase inhibitors and bone health"],"prefix":"10.1097","volume":"21","author":[{"given":"Nigel J","family":"Bundred","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"R6-11-20210129","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid effectively prevents cancer treatment induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Study of Osteoporotic Fractures Research Group, Endogenous hormones and the risk of hip and vertebral fractures among older women","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/JBMR.040508","article-title":"Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50\u201364 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA)","volume":"19","author":"Siris","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: a meta-analysis","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"Van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1586\/14737140.8.9.1377","article-title":"IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole","volume":"8","author":"Cuzick","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and non vertebral fractures from 2 US databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R23-11-20210129","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Current Opinion in Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/GCO.0b013e32831da80e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:27:27Z","timestamp":1786037247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001703-200902000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/gco.0b013e32831da80e","relation":{},"ISSN":["1040-872X"],"issn-type":[{"value":"1040-872X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}